News
-
-
-
PRESS RELEASE
Heidelberg Pharma to Present New Clinical Data on Lead ATAC Candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026
Heidelberg Pharma to present new clinical data on lead ATAC candidate Pamlectabart Tismanitin at International Myeloma Society Annual Meeting 2026 -
-
-
-
-
-
-
PRESS RELEASE
Capital B confirms the acquisition of 376 BTC for EUR 25.3 million, the holding of a total of 3,521 BTC, and a BTC Yield of 2.17% YTD
Capital B confirms acquisition of 376 BTC for €25.3 million, reaching total of 3,521 BTC with BTC Yield of 2.17%. Completes capital increases and raises, targets Bitcoin Treasury Company strategy